Platelet concentrates (PCs) have become widely used in veterinary and human medicine. The PCs consist mainly of supraphysiological concentrations of platelets and, therefore, growth factors (GFs) which are stored within platelet α-granules. Among PCs, Platelet-Rich Plasma (PRP) is characterised by low-density fibrin. Research on the effect of PCs in cattle has surged in recent years; in particular, evidence has shown the positive use of PRP for treating reproductive problems, in vitro production of bovine embryos, sole ulcers and udder diseases. The aim of this report is to critically review, in accordance with the PRISMA guidelines, the available literature reporting clinical application in the bovine practice of PRP. Three bibliographic databases PubMed, Web of Science and Scopus were used for a broad search of “platelet concentrates” OR “PRP” OR “platelet-rich plasma” OR “PRF” OR “platelet-rich fibrin” AND “cows” OR “cattle”. From 1196 papers, only six met the inclusion criteria. Two papers described the use of PRP in mastitis, two papers in uterine dysfunction and two papers in ovarian dysfunction. PRP offered a low-cost, easily obtained therapeutic option and showed positive results for these patients. However, given the different pathologies and definitions involved, further studies are necessary to assess its full clinical potential.

(1) Background: The aim of this prospective study was to evaluate the efficacy of topical application of leukocyte- and platelet-rich fibrin (L-PRF) membranes for treating chronic cutaneous wounds in dogs. (2) Methods: Chronic wounds unresponsive to conventional treatments were assessed on digital photographs and classified using the Bates-Jensen Wound Assessment Tool (BWAT). Each lesion was treated with L-PRF membranes. Epithelialization, granulation tissue formation, wound healing rate, and contraction were statistically analyzed during follow-up. (3) Results: All but one of the cases were treated with a single application of L-PRF for a median of 30 days after onset. All wounds healed after a median of 22 days. The BWAT score, total wound area, and granulation tissue decreased significantly over time while wound contraction increased. The most significant reduction in the total wound area was observed within the first 3 weeks after treatment. None of the dogs required the administration of antibiotics. (4) Conclusions: L-PRF membrane promoted the wound healing process in dogs and is a valuable and cost-effective tool for treating chronic wounds, thereby reducing the need for antibiotics administration.

Hospital-acquired infections in operating rooms are contributing factors to the increasing presence of pathogens, with surgical site infections being the most frequent among them. Surgical antimicrobial prophylaxis is administered to minimize the risk of developing surgical site infection. Surgeons are responsible for weighing the benefit of surgical site infection-risk reduction for the individual patient afforded by prophylactic antimicrobial administration against the broader societal risk from such use. The aim of this study was to analyze the data on surgical antimicrobial prophylaxis related to patient status, surgery duration, wound classification and the occurrence of surgical site infection in two operating rooms of the Veterinary Teaching Hospital of Naples from January 2023 to January 2024. Two hundred seventy-seven surgical procedures met the inclusion criteria. For soft tissue clean-contaminated procedures and clean orthopedic surgeries not involving implants, no statistically significant difference was observed between the various antibiotic protocols used and surgical site infection; this finding supports the possibility of avoiding antibiotic use for these procedures. In contrast to previous reports, this study identified a statistically significant association between ASA status and surgical site infection; no correlation was found between surgical duration and the occurrence of infection. Further research on antibiotic use and risk factors associated with surgical site infection will be crucial to strengthen clinical guidelines.

Osteoarthritis in dogs is commonly managed with non-steroidal anti-inflammatory drugs (NSAIDs), nutraceuticals, and other medications aimed at alleviating pain and inflammation. Although NSAIDs are generally considered the most effective option, their use is contraindicated in certain conditions due to adverse side effects. Consequently, there has been growing interest in alternative or complementary therapies, such as acupuncture, laser therapy, and their combination. Laser acupuncture involves stimulating traditional acupuncture points with low-intensity laser light, producing anti-inflammatory, analgesic, anti-edematous, and bio-stimulatory effects. In this study, 19 dogs with osteoarthritis were assigned to two groups: 10 received laser acupuncture treatment (Group T) using a dual-wavelength system delivering continuous and pulsed, synchronized emissions, while 9 served as controls (Group C). After 30 days, only Group T showed significant improvement (p < 0.01), with reduced pain and improved joint mobility. Significant reductions in LDH and CPK were observed in Group T, along with changes in inflammatory markers (IL-6 and IL-10, though not TNF-α) and a significant increase in biological antioxidant potential. These preliminary findings indicate that laser acupuncture, applied according to a standardized protocol and adapted to the site of disease, may represent a viable non-invasive therapeutic option for canine osteoarthritis, particularly in cases where pharmacological treatment is contraindicated or ineffective. Further large-scale, randomized controlled trials are warranted to confirm these results and establish long-term efficacy.

(1) Background: postoperative surgical-site infections are a significant complication in small-animal surgical procedures, with detected rates ranging from 0.8% to 18.1%, depending on the type of surgery. The sterilization process of surgical instruments is a crucial factor in infection control, but the shelf life of surgical instruments and the best packaging method are not precisely defined due to the multiple variables that influence them. This study aimed to assess the shelf life of surgical instruments stored under controlled environmental conditions in a veterinary hospital and compare two packaging methods: using a self-sealing single pouch versus a self-sealing double pouch. (2) Methods: a sample of 400 non-sterile screws was divided into three groups: Group 1 (175 screws in single pouches), Group 2 (175 screws in double pouches), and Group 3 (50 non-sterile screws as a control group to verify the microbial culture efficiency). Microbiological tests were conducted at 1, 7, 15, 30, 60, 182, and 390 days post-sterilization. (3) Results: no bacterial growth was detected on screws packaged in single and double pouches up to 182 days. However, after 390 days, bacterial growth was observed in one screw packaged in a single pouch. In Group 3, only two screws turned out to be bacteriologically positive. (4) Conclusions: no statistical difference was found between the two groups; however, the detection of a single positive screw in the single-pouch group raised a potential clinical consideration, suggesting the need for further studies based on events and time.

Degenerative lumbosacral stenosis is a multifactorial condition with no consensus on optimal therapeutic management. In mildly affected dogs, treatment often includes analgesics and non-steroidal anti-inflammatory drugs, which may be insufficient for effective pain control. This study aimed to evaluate the efficacy of amantadine in managing chronic neuropathic pain associated with this pathology in dogs, using ground reaction forces (GRFs) analysis, including Peak Vertical Force (PVF), Vertical Impulse (VI), and stance time (ST), and to evaluate whether the co-administration of amantadine improves the efficacy of meloxicam in patients who have shown a refractory response to meloxicam alone. Client-owned dogs (≥ 12 months old, ≥ 20 kg) with a confirmed diagnosis of degenerative lumbosacral stenosis were enrolled in a randomized trial. Subjects were assigned to two treatment groups: Group A received meloxicam (0.2 mg/kg PO SID loading dose, followed by 0.1 mg/kg SID for 6 days) plus amantadine (3 mg/kg PO SID for 21 days); Group B received amantadine alone (3 mg/kg PO BID for 21 days). Gait analysis was performed using a force platform at baseline (T0), after 7 days (T1), and after 21 days (T2). Twenty dogs met the inclusion criteria and completed the study. At enrollment, the two groups (10 animals each) were homogeneous. After 21 days, both groups showed significant increases in PVF%BW (p < 0.0001) and VI%BW (p = 0.0064 in Group A; p = 0.0023 in Group B). For VI%BW, Group A demonstrated a significant improvement between T0 and T1 (p = 0.0120), and T0 and T2 (p = 0.0083), but not between T1 and T2 (p = 0.4040). Group B showed significant increases between T0 and T2 (p = 0.0012), and T1 and T2 (p = 0.0034), but not between T0 and T1 (p = 0.7788). Regarding PVF%BW, both groups exhibited significant differences across all time points, showing progressive improvement over time. The results suggest that amantadine, either alone or in combination with meloxicam, improves GRFs in dogs with degenerative lumbosacral stenosis and, may be a valuable component of its multimodal therapy, though additional research is necessary to validate these findings.